<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112043</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201900746 -N</org_study_id>
    <secondary_id>OCR26682</secondary_id>
    <secondary_id>5R21AG064282</secondary_id>
    <nct_id>NCT04112043</nct_id>
  </id_info>
  <brief_title>Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)</brief_title>
  <official_title>Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 80% of older adults have hypertension, with higher prevalence of high systolic&#xD;
      blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death.&#xD;
      Novel compound, nicotinamide riboside may enhance the effects of exercise therapy in&#xD;
      hypertensive older adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SBP</measure>
    <time_frame>Baseline; Week 6</time_frame>
    <description>SBP will be measured every 20 minutes (min) during the day (from 0700 to 2200 hours), and every 60 min overnight (from 2200 to 0700 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>Baseline; Week 3; Week 6</time_frame>
    <description>Aortic pulse-wave velocity (PWV), commonly measured as carotid to femoral PWV (cfPWV), will be measured using the SphygmoCor XCEL system. Briefly, cfPWV will be determined by recording pressure pulse waves at the carotid and femoral arteries using a high-fidelity micromanometer and calculating the distance between the recording sites divided by the time delay between the carotid and the femoral pulse waves.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>NR plus Walking Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Walking Exercise plus Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NR Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Walking Exercise</intervention_name>
    <description>Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.</description>
    <arm_group_label>NR plus Walking Exercise</arm_group_label>
    <arm_group_label>Walking Exercise plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide Riboside (NR)</intervention_name>
    <description>Participants randomized to this intervention will receive 1,000 mg/day of NR.</description>
    <arm_group_label>NR Alone</arm_group_label>
    <arm_group_label>NR plus Walking Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Daytime average of systolic blood pressure of &gt;130 mmHg and &lt; 160 mmHg. We will&#xD;
             recruit participants without an active hypertension medication treatment.&#xD;
&#xD;
          -  Sedentary lifestyle, defined as &lt; 150 min/wk of moderate physical activity as assessed&#xD;
             by the CHAMPS questionnaire.&#xD;
&#xD;
          -  Willingness to be randomized to either treatment group&#xD;
&#xD;
          -  Willingness to participate in all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to provide informed consent;&#xD;
&#xD;
          -  Change in blood pressure therapy (type or dose) within the last 3 months- Temporary&#xD;
             Exclusion&#xD;
&#xD;
          -  Daytime average of systolic blood pressure &gt; 160 mmHg.&#xD;
&#xD;
          -  Regular consumption of nicotinamide riboside supplement&#xD;
&#xD;
          -  Current involvement in supervised rehabilitation program&#xD;
&#xD;
          -  Absolute contraindication(s) to exercise training according to American College of&#xD;
             Sports Medicine guidelines&#xD;
&#xD;
          -  Daytime average of systolic blood pressure below 130mm Hg or Diastolic BP â‰¥ 100mm Hg.&#xD;
&#xD;
          -  Peripheral vascular disease; peripheral neuropathy; retinopathy&#xD;
&#xD;
          -  Severe cardiac disease, including NYHA Class III or IV congestive heart failure,&#xD;
             clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac&#xD;
             defibrillator, or uncontrolled angina;&#xD;
&#xD;
          -  Myocardial infarction or stroke within past year&#xD;
&#xD;
          -  Significant cognitive impairment, including known dementia diagnosis or a Mini-Mental&#xD;
             State Examination exam score &lt; 24&#xD;
&#xD;
          -  Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple&#xD;
             sclerosis;&#xD;
&#xD;
          -  Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active&#xD;
             inflammatory disease;&#xD;
&#xD;
          -  Severe pulmonary disease, requiring either steroid pills or injections or the use of&#xD;
             supplemental oxygen;&#xD;
&#xD;
          -  Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;&#xD;
&#xD;
          -  Other significant co-morbid conditions that would impair ability to participate in the&#xD;
             exercise-based intervention&#xD;
&#xD;
          -  Simultaneous participation in another intervention trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Mankowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UF Institute on Aging</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Roberts</last_name>
      <phone>352-273-5919</phone>
      <email>recruit@aging.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Mankowski, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systolic blood pressure (SBP)</keyword>
  <keyword>cardiovascular (CV) disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

